A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv14
  2. Study sites: 10 to 11v13
  3. 2 versions Re-verified since Jun 4, 2026, no change to tracked fieldsv11-v12
  4. Study sites: 9 to 10v10
  5. Study sites: 8 to 9v9
Show 7 earlier versionsHide 7 earlier versions
  1. 2 versions Re-verified since Feb 12, 2026, no change to tracked fieldsv7-v8
  2. Study sites: 7 to 8v6
  3. Study sites: 5 to 7v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study sites: 3 to 5v3
  6. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
Trial Details
NCT Number NCT07141004
Lead Sponsor Johnson & Johnson Private Limited
Conditions
(from sponsor)		 Arthritis, Psoriatic
Related terms Arthritis, Psoriatic
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov